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Identity 
Hugo: ATF2 
Other names: CREB1; CRE-BP1; CREB2; CREBP1; 
HB16; MGC111558; TREB7; Cyclic AMP-dependent 
transcription factor ATF-2; cAMP response element-
binding protein CRE- BP1 
Location: 2q31.1 
 
DNA/RNA 
Description 
Gene size: 115.93Kb. 
 
ATF2 gene structure based on data available in the Ensembl 
release 44. Upstream non-coding exons (green). Coding exons 
(pink), 3' untranslated sequence (red). The size of the exons in 
nucleotides is indicated below each exon. Exon number is 
indicated within the exon. 
Transcription 
Initiation codon located in exon 4. Normal message is 
2109 nucleotides. Some alternatively spliced RNA 
messages have been detected; but they are likely to 
represent splicing intermediates since no protein has
been detected/expressed from these alternative 
messages in humans. 
 
 
 
Protein 
Note: Protein of 505 aminoacids and a size of 52.27 
kDa. Functions as a dimer, either homodimer or 
heterodimer with proteins of the jun family (e.g.: c-Jun, 
c-Fos). 
 
Localisation 
Nuclear protein. 
Function 
Transcription factor which binds to the cAMP-
responsive element (CRE) (consensus: 5'-
GTGACGT[AC][AG]-3'). ATF2 binds DNA as a 
dimer. The specificity of the DNA target sequence that 
is recognized by dimers containing ATF2 is different 
depending on whether it is a homodimer or it forms a 
heterodimer with another JUN protein. 
Mutations 
Note: Lung cancer. 
Somatic 
G to A transition in exon 10. Val258Ile Substitution. 
Implicated in 
Clear cell sarcoma 
Cytogenetics 
t(2;12)(q31.1;q13) 
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The arrow indicates the location of the breakpoint in chromosome 2. The ATF2 gene breaks within intron 6. In the translocation partner 
EWS the breakpoint occurs in intron 7. The transcript resulting from the hybrid gene fuses exon7 of EWS to exon 7 of ATF2. 
Hybrid/Mutated Gene 
EWS -ATF2 fusion transcript. 
Abnormal Protein 
The EWS-ATF2 fusion protein retains the ATF2 C-
terminal region that contains the bZIP dimerization 
domain. But the fusion protein has lost the N-terminal 
domain of ATF2 that is kinase inducible. The N-
terminal region of EWS is retained in the fusion protein 
but has lost both its RNA binding domain and its Zinc-
finger Ran binding domain. 
 
 
 
Structure of the EWS-ATF2 fusion protein. 
Oncogenesis 
EWS-ATF2 may define a novel subset of clear cell 
sarcoma that occurs preferentially in the 
gastrointestinal tract and presents little or no 
melanocytic differentiation.  
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